UNASSIGNED: The aim of the present study was to investigate the long-term survival of @entity1 with @entity2799 ( @entity2799 ) that were administered alternately with compound realgar natural indigo tablet (CRNIT) treatment and chemotherapy. In total, 31 @entity1 with refractory @entity2799 were administered with CRNIT treatment alternately with chemotherapy. The complete remission (CR) and relapse rates were estimated by bone marrow (BM) examination. The expression of the @entity2799 - @entity1968 receptor a (PML-RARa) fusion protein and the apoptosis rate in the @entity1968 (RA)-resistant @entity1 -R1 cell line administered with CRNIT treatment in vitro were measured by western blot analysis and flow cytometry, respectively. The @entity1 were followed up for 12-60 months, with a median follow-up time of 43 months. The total continuous CR rate was 90.32% (28/31), and the duration of response was between 10.3 and 60 months (median, 42.4 months). The total relapse rate was 9.68% (3/31), and the median time of relapse was 13 months (range, 8-27 months). During the treatment with CRNITs, there was no evident BM @entity308 and only limited side-effects were experienced. Additionally, in vitro cell molecular biology results revealed that CRNIT treatment resulted in a marked induction of apoptosis and degradation of the PML-RARa fusion protein. The present results revealed that CRNIT treatment in combination with chemotherapy is an effective and feasible therapy for the treatment of @entity1 with refractory @entity2799 .

Long-term outcome of 31 cases of XXXX treated with compound realgar natural indigo tablets administered alternately with chemotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'NB4'] @entity2799 :: ('MESH:D015473', 'Disease') :: ['APL', 'promyelocytic leukemia', 'refractory acute promyelocytic leukemia'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid']
@entity2799 :: (MESH:D015473,Disease) :: ['refractory acute promyelocytic leukemia']
